AEON Biopharma, Inc.

Aeon Biopharma, which is working on developing a biosimilar version of Botox (onabotulinumtoxinA) in the US, has looked to rival developer Revance Therapeutics to recruit its new chief executive. Aeon

AEON Biopharma has kicked off the primary analytical studies that are required for its ABP-450 proposed biosimilar to Botox (onabotulinumtoxinA) to fulfill the standard regulatory requirements for a c

Botox biosimilar hopeful AEON Biopharma saw its stock drop by more than two-thirds after raising gross proceeds of around $20m via an underwritten public offering to fuel the development of its propos

After meeting with the US Food and Drug Administration, Aeon Biopharma appears confident about the next steps for its ABP-450 (prabotulinumtoxinA) proposed biosimilar to Botox. Announcing receipt of